<SEC-DOCUMENT>0001193125-13-449990.txt : 20131121
<SEC-HEADER>0001193125-13-449990.hdr.sgml : 20131121
<ACCEPTANCE-DATETIME>20131121171806
ACCESSION NUMBER:		0001193125-13-449990
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20131119
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20131121
DATE AS OF CHANGE:		20131121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		131236060

	BUSINESS ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d633425d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) of the </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): November&nbsp;21, 2013 (November 19, 2013) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ARCA biopharma, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>000-22873</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>36-3855489</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Commission File Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>11080 CirclePoint Road, Suite 140, Westminster, CO 80020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(720) 940-2200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
Name or Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE="font-family:Times New Roman; font-size:10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE="font-family:Times New Roman; font-size:10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE="font-family:Times New Roman; font-size:10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE="font-family:Times New Roman; font-size:10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Item&nbsp;5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment
of Certain Officers; Compensatory Arrangements of Certain Officers. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On November&nbsp;21, 2013, ARCA announced that
Dr.&nbsp;John Zabriskie resigned from the Board of Directors of ARCA biopharma, Inc. (&#147;ARCA&#148;) on November&nbsp;19, 2013. Dr.&nbsp;Zabriskie&#146;s resignation was not the result of any disagreements with the Company relating to its
operations, policies or practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On November&nbsp;21, 2013, the ARCA Board of Directors appointed Dr.&nbsp;Raymond
Woosley to the Audit Committee of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A copy of the press release announcing Dr.&nbsp;Zabriskie&#146;s resignation
is attached hereto as Exhibit 99.1. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9 &#151; Financial Statements and Exhibits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.75pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;ARCA biopharma Announces Resignation from Board of Directors&#148; dated November 21, 2013.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: November&nbsp;21, 2013 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARCA biopharma, Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Registrant)</P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Christopher D. Ozeroff</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Christopher D. Ozeroff</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">SVP and General Counsel</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9 &#151; Financial Statements and Exhibits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.75pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;ARCA biopharma Announces Resignation from Board of Directors&#148; dated November 21, 2013.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d633425dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g633425g42l43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCA BIOPHARMA ANNOUNCES RESIGNATION FROM BOARD OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Westminster, CO, November&nbsp;21, 2013</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that John L. Zabriskie, PhD, has
resigned from the Company&#146;s Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Zabriskie resigned effective November&nbsp;19, 2013. There has been no
disagreement between the Company and Dr.&nbsp;Zabriskie. Dr.&nbsp;Zabriskie has served as a member of ARCA&#146;s board of directors since March 2005. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;I want to express our deep gratitude and appreciation for John&#146;s contributions to ARCA and the Board,&#148; commented Michael
Bristow, MD, PhD, President and CEO of ARCA. &#147;John has been a tremendous asset, sharing his extensive experience and wisdom from a highly successful career in our industry. We will miss his sage advice and steady hand in guiding the
Company.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Zabriskie is Co-Founder and Director of Puretech Ventures, LLC, and the past Chairman of the Board, Chief
Executive Officer and President of NEN Life Science Products, Inc., a supplier of kits for labeling and detection of DNA. Prior to joining NEN Life Science Products in July 1997, Dr.&nbsp;Zabriskie was President and Chief Executive Officer of
Pharmacia and Upjohn Inc. Prior to joining Upjohn in 1994, Dr.&nbsp;Zabriskie was Executive Vice President for Merck&nbsp;&amp; Co., Inc. Dr.&nbsp;Zabriskie received his undergraduate degree in chemistry from Dartmouth College and his Ph.D. in
organic chemistry from the University of Rochester. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor&nbsp;&amp; Media Contact: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derek Cole </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">720.940.2163 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>derek.cole@arcabiopharma.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g633425g42l43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g633425g42l43.jpg
M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!K`+(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBL
M[6IVAT\[3C>P0GVY/]*PQ-=4*,JLNBN5"/-)1))=6LXG*F3<1UVC-,&LVA[O
M_P!\US\,1?MDU>CM"P4XX(/YBO"P^/Q]?WDDEZ/_`#.N5&G'<TCK-H.I?_OF
MK%O>V]UD12`D=0>#6#+;%5&1R1G\*IAWMIEE0X*G(J:N:8S#34JJ3CULK/\`
M,%AX27NO4[*BFHV]%;IN`-.KZ5.ZNCB"BN.\=ZO+9Q6UI;.RREA,Y7^%0<+G
MZG^5=1IUXFH:=;W:?=E0-CT/<?G3`LT4UU#HR$D!@1E3@CZ'M7G_`(M:\T&Y
MM_LFJWY2=6)62=FQC'3\Z`/0J*P8?#[-9)NUC5/.*@F07)ZX]/2LGP_X@OH]
M?ET/4Y/.8,R1RD8.1D\^H(%`':455U"_M],L9+NY;;%&.<=2>P'O7+Z9-JWB
MR1[F2XDL=,5MJ)`<-)_P+^9_2@#LJ*QF\+:6R8"3J_\`ST$[[OYUFZ1;7^D>
M*&LKF\FN+6:!F@,CD\@C/![@?SH`ZNBBN<\::FUAHAAB)$]R=B[>H4<L?RX_
M&@#HZ*R/#.H_VIH%M.S9D4>7)Z[EX_48/XUKT`%%%%`!63XA_P"/&+_KJ/Y&
MM:L;Q,VW3HC_`--A_)JX,SM]4J7[&M#^(BG81&0C]W(?]I1TJU%<F6Y=%;:@
M8CCC/;-95A<*'7Y=S=@3@?C5I[64SM+:R(R.Q."<<XR<>U>=0JM4XN"NNMCJ
MG'WG<U)4#ADY8@9^4<D>E8-XI4D%"OL:T0WD0MYK+)(R@[<G[OL?6L2[G4D[
M<@>]9YI4@Z/O#H1?,=M!_P`>\7^X/Y4\D`$D@`=2:9;_`/'M%_N#^58'C;4I
M+'0&M[<YO+]Q:P*#R2W!_3/XD5]#3^!>AP/<S[:Q/B;3-<U`C)O28[3/9(_N
MD>F6'-1?#?5//T^YTYS\]N^]`>NUNOY'^=:=MX*L;>VCA6]U$;%`PEVRKGO@
M#I7%Q8\&?$V.#>WV.XPH9VR2C\9)]F'Z58CUFO./B>^RYTWG^"3^:UZ/7EWQ
M:DV76E^Z2?S6@#M_^$HT.VL4DDU6U("#*I*';IZ#FN=\.:/>ZCXGF\0W<#VU
MN9'>&.089L\#CT`/XU/XO\*PZGX>6ZL;=$OK>,.!&H!D7'*G'4]Q^7>D^'?B
M@:QIO]G7,F;VU7@D\R1]`?J.A_"@"C\3;]DDL;$-A,-*P]3T']?SKN-)M4LM
M(M+9`,1Q*..YQR?Q/-<%\5[*01V&HHI,:EH9#Z9Y7_V:NV\/:E'J_A^RO8V!
MWQ`.!V8<,/S!H`TZ0HI96*@LO0D<BEJM>:A;6'D?:)-IN)E@B&"2SMT%`%FN
M7@C3Q!XBU223YK2UB-C'Z%V'[PCW'2M3Q%JRZ)H%W?L0&C3$8/=SPH_,BL/0
M_!D,>CVS75UJ$=S(@DF$=RR#>W)X'?M^%`&7X!O'T_6]0T.X.'#$J/\`:4X.
M/J.?PKT2O(_%%I_PAGB_3=2MWFD@<B0M*Y9B0<.,GK\I'YUZU'(DL221L&1P
M&5AT(/0T`.HHHH`*S-=LY+W3&2(9D1@ZKZXSQ^1K3HK*O1C7IRI2V:L5"3A)
M270\U6=HF(.01P0:NQ:H5Q\W12H_'/\`C7:3:?9W+[YK6%W_`+S("?SJ/^Q]
M-_Y\H/\`O@5\_2R;$T=(5%;YG<\73EO$XJ74"ZJ,].E-LX)M1NUAB4G)^8]E
M'J:[?^Q]._Y\H/\`O@59AMX;9-D$21KZ(H%#R2M5FO;U/=\@>,BE[BU$E+6]
MHYAA:9XXR4B#`%R!PN3P,].:\]U&U\9:CXJL-8DT*/[+8DF*T-Y'GD<DMG&[
MI[<#ZUZ/6;_:K-KW]EI;D[8_->4L,`=L#Z^N*^E2L>>6[.::>TCEN+9K:5AE
MH6=6*?BI(/X5YKXUT'Q+XKO;::WT(6HMU9-[W<9:0$@CH>`.?SKTZ5S'$[A&
M<JI.U>I]A4=G<-=6D<[020,XR8Y!AE^M`&#H-_XF%N+?6=$Q+%$2+F*YC(E8
M#@%<Y!/KT^E<?XQT/Q;XMNK:5=#2TBMU955KN-F.3R3@X[#BO5:;O3S/+W+O
MQG;GG'KB@#%\/WFN2QI;:OHPM&CB'^D)<(Z2,,#`4'([GTXZUQ.L^"]>TSQF
MNL>&($:)CYNUI%4(Q^\A!(RI]O7'&*]+O+@6=G-<E"PB0N0"!P.O6H]+O'U#
M3H;MXO*\T;@F<X&>/TYH`S;47NO:?<V/B'0UM8W0*P%PLJR?3'((P#S^!KE[
M#P_XF\$WLIT94U;2I6W-:M((Y%]QGC..,CKZ=*]%HH`YK_A*+]HAY?A36#.1
M]UQ&J9_WMW]*QK+2?%6L>,K+5]<@AM+*TW&*U68/M)4@=,Y.<$GVKOJ*`/.?
M%%KXO\1S6:QZ%'!96TPF:&2[C)E(/\6#@#&>.>M=UIMS=W=IYE[8-8S;B/*:
M59./7*\5<HH`\^\>Z7K_`(FB2QL]#"I;S;TNI+J,;Q@C`7.0#P>?2K_A%_%6
MFVEKI>KZ.'@C&Q;N.Y0E$'0,N<G'3BNRHH`****`"BBB@`HHHH`****`&NZQ
MHSN0JJ,DGL*\_2?5)H+G6;:X,$FH72):QA`6E`.`#GHH&>G7%=Y=6Z7EG/;2
M%@DT;1L5.#@C!Q5#3=!@T[R6::6YD@3RX6FQ^Z7IA0``/<]3ZT`5O%-[>VUK
M;P6$JQW%U*(DP,L2?3T&,Y/;CUS4FLZA<V4=C86SJ;Z\?RDD8<*`/F?'?'I4
MNH:!;:GJ=O>7,DQ$"%1"&PC9ZY[\]#ZCBIM0TM+^:VG$TD%Q;%C%+&`2-R[2
M,$$=/Y4`4M"O)IM1U6T::2>"TD1(Y9,;BVWYP2/0C]:YJZNKPIJWB".\9)H)
MUM;?RE&V0!@",'.1SGZ@UOZE-9>$?#-P()`DA5C'YCY>64\;CZG)!--T+P[#
M%IFG&:YDN$A`F2+*F,2GDMP/FP2<9/%`#O%US,NA):0KFZOI%A5!UYY/\L?C
M3-.-_:^)DT][HRP)9!Y(P@"1'=A57OT'?DUJWVD17]U#<O--'+#'(D10@!"X
MP6''WAVI^G:;'I\;XEDGFD(,L\IR[X&!D^PH`R-7U]HK6]FMIA#!;$Q"3:&:
M6;^XH/&!W./7'3-3S2WVE^$6GGN<W<<.^25QD@GG`'3/856/@FR:*-&O;TB*
M?SDS(/E.<D`8QR>_6M:^T:UO]-33Y-Z6RE3LC.-P4Y"G.>./K0!F^'H-9GMK
M*^O]1?:4)-L8Q\P/W23Z]_R]ZSK_`%C4AKU^L=ZL5C90DSLB@A,_=`R.7/'7
M@$GCCGL\8&!6(?"]BUD;5Y;AHWN?M4Q+#,S9SAN.1[#'2@#!TF^URXO-(MYK
MQ_,=3/+'M'$.>"Y]3T'IQWKI=0U,QW1LX'1)%C,T\S\K!'ZGU)[#\?JD6@VT
M>MSZJTDLDTNW".?D3`P,#_/6JU_X5M=0O+VXENKI?M:*KQH^%^48!QCG'H>,
MT`.\,3W5[9SW]Q<2RQSRG[.)``1&.`<``9-;E4],TV#2K)+6#<54#+.<LQ``
MR?P`'X5<H`****`"BBB@`HHHH`****`"BBB@`HHHH`:\:28WHK8Z9&:555%"
MJH51T`&*6B@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
FHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
